Prothrombin Complex Concentrate (PCC) Market by Global Industry Trends, Growth, Size, Segmentation, Future Demands, Latest Innovation

Global Prothrombin Complex Concentrate (PCC) Market to Grow with Increasing Popularity of 4-Factor PCC Products

Prothrombin Complex Concentrate MarketThe global prothrombin complex concentrate (PCC) size is poised to reach USD 1,076.5 million by 2025, registering a CAGR of 9.1% during the forecast period. Rising prevalence of hemophilia across the globe is expected to be a major growth driver for this market. Hemophilia is a rare blood disorder wherein normal blood clotting does not occur due to absence or insufficient amount of clotting proteins in the individual’s blood. Though rare, the disorder has been found to have increased in prevalence. According to a study led by Canada’s McMaster University, more than 1,125,000 men worldwide suffer from this inherited affliction. PCC treatments have been found to be highly effective in managing hemophilia, a study published in JAMA Pediatrics, a peer-reviewed medical journal, found. This bodes well for the prothrombin complex concentrate market growth as adoption rate of PCC therapeutics picks up pace.

Request a Sample Copy of Research Report:

According to the Fortune Business Insights report, titled “Prothrombin Complex Concentrate (PCC) Market Size, Share and Industry Analysis By Product Type (3-factor PCC, 4-factor PCC), By Application (Congenital and Acquired Coagulation Factor deficiency), By End User (Hospitals, Ambulatory Surgical Centers), and Regional Forecast 2018-2025”, the market value stood at USD 536.3 million in 2017. The report also contains a bird’s eye-view analysis of the overall industry outlook and a worm’s eye-view assessment of the various factors, future prospects, upcoming trends, regional dynamics, and competitive landscape that will shape the market in the forecast period.

Fortune Business Insights identifies the following players in the PCC market:

  • Sanquin
  • China Biologic Products Holdings, Inc.
  • Grifols SA
  • Shire
  • Octapharma AG
  • Kedrion S.p.A
  • CSL Behring

For more information in the analysis of this report, visit:

Growing Utilization of 4-Factor PCC to Boost Sales

The 4-factor prothrombin complex concentrate (4F-PCC) is used to expedite the reversal of vitamin K antagonist (VKA). It carries several benefits which is fuelling its popularity. For example, this PCC variant contains coagulation factor VII, which is not present in other variants. Furthermore, administering 4F-PCC is relatively easy as it requires a reduced infusion volume and it also minimizes the risk of pathogen transmission. Effectivity of its treatment mechanism has surged its adoption rate and given it international recognition. For instance, the British Committee for Standards in Haematology has prescribed specific guidelines for the deployment of PCC techniques in treating haemophiliacs. These developments are expected to provide a positive thrust to the market for this medication technology.

Operational Diversification by Players to Intensify Competition

According to the prothrombin complex concentrate market trends, key players are adopting strategies to expand, disperse, and diversify their operational reach with a view to strengthen their position in the PCC market. This is being accomplished through partnerships with other companies and acquisition activities.

Key industry developments:

  • June 2017: The Chinese plasma fractionator, Wuhan Zhong Yuan Rui De Biological, was acquired by CSL Behring to establish CSL’s presence in the plasma fractionation market in China. This move was further vindicated when CSL’s PCC brand, Kcentra, got cleared for commercial release in Japan.
  • August 2018: Grifols S.A. took over 24 plasma donation centres in the US, thereby strengthening its supply of plasma proteins for blood disorder treatments.

More Trending Topics from Fortune Business Insights:

Cardiovascular Stents Market 2019 Movements by Top Key Players, Trends, Growth, Revenue Expectation to 2025 | Research Report by Fortune Business Insights

Contraceptives Market Size to Worth USD 31,666.9 Million by 2025 | Fortune Business Insights

Transrectal Ultrasound (TRUS) Market to Exhibit CAGR of 4.5% By 2025 | GE Healthcare, BK Medical Holding Company, Inc., KOELIS, Exact Imaging and more till 2025

About us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *